The Value of PD-L1 Expression in Metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer

Haitang Yang,Sean R. R. Hall,Feng Yao

DOI: https://doi.org/10.1016/j.chest.2020.06.077

IF: 9.6

2020-01-01

Chest

Abstract:Programmed death-ligand 1 (PD-L1) protein expression is the only approved biomarker to predict benefit from immune checkpoint inhibitors (ICI). In advanced non-small cell lung cancer (NSCLC), lymph nodes (LN) are common metastatic sites. Thus, for unresectable NSCLC, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) represents an essential approach for diagnosis and LN staging. However, the value of PD-L1 expression in involved LN in predicting response to ICI treatment remains unclear. In a recent issue of CHEST (September 2020), Perrotta et al1Perrotta F. Nankivell M. Adizie B. et al.Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer.Chest. 2020; 158: 1230-1239Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar retrospectively evaluated the performance of PD-L1 expression in specimens obtained by EBUS-TBNA in patients with NSCLC compared with other approaches, which showed that EBUS-TBNA provided adequate sampling for reliable PD-L1 testing in 95% (179/189) of patients. Additionally, higher N-stagewas independently associated with high PD-L1 expression. This study highlighted EBUS-TBNA as a suitable approach not only for sampling but PD-L1 testing in advanced NSCLC. Despite the conclusions by Perrotta et al,1Perrotta F. Nankivell M. Adizie B. et al.Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer.Chest. 2020; 158: 1230-1239Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar several questions remain. First, apart from the inadequate sampling by unresected approaches because of high intra-tumor heterogeneity,2Pinato D.J. Shiner R.J. White S.D. et al.Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: implications for immunotherapy.Oncoimmunology. 2016; 5e1213934Crossref PubMed Scopus (51) Google Scholar the role of metastatic LN itself in evaluating PD-L1 expression and predicting response to ICI treatment in NSCLC remains a question. A study demonstrated heterogeneous PD-L1 expression among different metastatic biopsy sites, including LN, in advanced NSCLC.3Hong L. Negrao M.V. Dibaj S.S. et al.Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC.J Thorac Oncol. 2020; 15: 1449-1459Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar Notably, compared with other biopsy sites, PD-L1 levels at the biopsy sites of involved LN could not predict therapy response rates nor prognosis in patients having received ICI treatment. This observation argued that PD-L1 expression level from LN biopsies is not suitable as a biomarker to guide ICI therapy. We extracted data from the MET500 cohort, which has analyzed 500 metastatic tumors across 20 cancer types.4Robinson D.R. Wu Y.M. Lonigro R.J. et al.Integrative clinical genomics of metastatic cancer.Nature. 2017; 548: 297-303Crossref PubMed Scopus (346) Google Scholar Comparing messenger RNA level of PD-L1 from different biopsy sites in metastatic NSCLC showed the heterogeneous PD-L1 expression in different biopsy sites, particularly LN (Fig 1). Although Perrotta et al1Perrotta F. Nankivell M. Adizie B. et al.Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer.Chest. 2020; 158: 1230-1239Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar observed all 11 patients with a partial response to ICI had high PD-L1 expression, how many of them were from the biopsied LN group were not clearly demonstrated. Further studies with a large cohort are needed. Second, a comparison of PD-L1 expression level between primary NSCLC and matched LN metastases is missing and would help guide ICI therapy, given that LN plays a critical role in facilitating rapid and efficient immunity. Recent evidence has demonstrated that stromal cells within LN can shape tumor immunity.5Krishnamurty A.T. Turley S.J. Lymph node stromal cells: cartographers of the immune system.Nat Immunol. 2020; 21: 369-380Crossref PubMed Scopus (48) Google Scholar Compared with the primary lung tumors, whether involved LN has a difference in expressing PD-L1 and predicting ICI response warrants further studies. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung CancerCHESTVol. 158Issue 3PreviewThis large multicenter study shows that EBUS-TBNA provides samples adequate for PD-L1 testing and that advanced N stage and the presence of brain metastasis are associated with high PD-L1 expression. Full-Text PDF ResponseCHESTVol. 158Issue 4PreviewWe thank Dr Yang and colleagues for their important comments. We agree that programmed death-ligand 1 (PD-L1) expression in metastatic lymph nodes may not necessarily reflect PD-L1 expression in primary non-small cell lung cancer (NSCLC). This has important implications because endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the recommended method for sampling metastatic hilar and mediastinal lymphadenopathy in suspected NSCLC. Indeed, studies investigating the concordance of PD-L1 expression on paired samples from primary tumor and lymph node metastases in patients with lung cancer show inconsistent results. Full-Text PDF